home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

HIF-1: A New Cancer Drug Target

  December, 3 2000 0:45
your information resource in human molecular genetics
All treatments for cancer are based on the concept of exploiting the difference between cancerous and normal cells. Chronic hypoxia—severely reduced oxygen flow to tissues—is a hallmark of many tumors, and causes changes in gene expression within tissues. One such gene, the transcription activator hypoxia-inducible factor 1 (HIF-1), is expressed in cells that lack oxygen and has become the object of cancer research because of its role in stimulating the expression of other genes that enable a cell to survive in hypoxic conditions.

Based on the idea that stopping the action of HIF-1 in cancerous cells would prevent their survival, David Livingston and colleagues at Harvard Medical School produced a polypeptide that interferes with the regulation of HIF-1 and its subsequent actions on other genes (Nature Medicine, Vol. 6, Issue 12, 01 Dec 2000). They show that the polypeptide is able to slow tumor growth in cells.

Peter Ratcliffe and colleagues from the Henry Wellcome Building of Genomic Medicine in the UK, discuss the clinical feasibility of the strategy as an anticancer treatment in a News & Views article.


Dr David M Livingston
The Dana-Farber Cancer Institute
Harvard Medical School
44 Binney Street
Boston, Massachusetts 02115
Tel:+1 617 632 3074
Email: david_livingston@dfci.harvard.edu

Dr Peter Ratcliffe
Professor of Medicine
Wellcome Trust Centre for Human Genetics
Oxford OX3 7BN
Tel: +44 1865 287531
Email: peter.ratcliffe@molecular-medicine.oxford.ac.uk

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.